drugset / Trial / NCT05842785
TSN222 in Subjects With Advanced Solid Tumors or Lymphomas
Non-randomizedSequentialOpen-labelTreatment
Summary
The study is a first-in-human \[FIH\], open-label phase 1/2 study of TSN222 in subjects with advanced solid tumors or lymphomas. This study is comprised of a Phase 1 dose escalation and Phase 2 dose expansion component.
Timeline
- Start
- 2023-07-26
- Primary completion
- 2025-06-01
- Completion
- 2026-06-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TSN222 | Unknown | 100 ug | Other |
| Subject | TSN222 | Unknown | 200 ug | Other |
| Subject | TSN222 | Unknown | 400 ug | Other |
| Subject | TSN222 | Unknown | 800 ug | Other |
| Subject | TSN222 | Unknown | 1600 ug | Other |
| Subject | TSN222 | Unknown | 3200 ug | Other |